Research programme: Bcl-2/Bcl-xl/Mcl-1 inhibitors - EvotecAlternative Names: Mcl-1 inhibitors - Evotec
Latest Information Update: 14 Jan 2010
At a glance
- Originator Evotec AG
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jun 2007 Preclinical trials in Cancer in Germany (unspecified route)